CA-DEXERIALS
22.3.2024 02:31:27 CET | Business Wire | Press release
Dexerials Corporation, (TOKYO: 4980) (Headquarters: Shimotsuke-shi, Tochigi, Representative Director and President: Yoshihisa Shinya, hereinafter “Dexerials”), which provides leading-edge technologies, materials, and devices for smartphones, automobiles, and other products, announces that the name of the integrated company to be created under Dexerials Precision Components Corporation (Headquarters: Tome-shi, Miyagi, Hereinafter “DXPC”) and Kyoto Semiconductor Co., Ltd. (Headquarters: Shimotsuke-shi, Tochigi, hereinafter “Kyoto Semiconductor”) has been determined as Dexerials Photonics Solutions Corporation (hereinafter “DXPS”), a consolidated subsidiary of Dexerials in Japan, and that DXPS will commence operation on April 1, 2024. In accordance with Dexerials’ news release on July 31, 2023, entitled Notice Regarding Launch of Integrated Company to Lead Growth in the Photonics Domain, preparations for a launch of the integrated company between DXPC and Kyoto Semiconductor had been made.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321222931/en/
Change in sales structure after the launch of DXPS (Graphic: Business Wire)
The profile of DXPS is as follows.
Profile of the integrated company
Corporate name |
Dexerials Photonics Solutions Corporation |
Head office |
Shimotsuke-shi, Tochigi |
Offices |
Eniwa Operation, Kamisunagawa Operation and Tome Operation |
Date of inauguration |
April 1, 2024 |
Share capital |
100 million yen |
Representative (planned) |
Kazuya Hayashibe, Representative Director and President |
Business |
Development, production and production management of optical semiconductors, optical devices and semiconductor-composite devices (photonics products) |
Dexerials Group will support DXPS in developing and providing solutions essential to the evolution of technologies in the photonics domain, aiming to increase efficiency in society. In so doing, the Group will help build a sustainable society, while aiming to achieve continuous growth and higher corporate value.
DXPS will develop and manufacture** microdevices and optical semiconductor device products that have been operated by DXPC and Kyoto Semiconductor. Dexerials will sell them to customers as its photonics products.
Dexerials and Kyoto Semiconductor will participate as an exhibitor at the OFC 2024 trade show that will take place at the San Diego Convention Center in San Diego in the United States from Tuesday, March 26 to Thursday, March 28. We cordially invite visitors to the exhibition to drop by our booth.
Comment from Kazuya Hayashibe, Representative Director and President (planned), DXPS
The Dexerials Group has been effectively combining technologies with the knowledge possessed by its human resources to offer materials and solutions indispensable to electronics and automobiles, aiming to link them to the evolution of digital technologies.
In the future, artificial intelligence (AI), Internet of things (IoT), next-generation communication and other new technologies will have increasing opportunities to play significant roles in boosting the efficiency of society for solving social issues. It is hence anticipated that optical semiconductors and the photonics solutions that support them will also have greater roles to play.
DXPS will lead the Dexerials Group’s business growth in the photonics domain. It will combine the optical semiconductor technologies cultivated by Kyoto Semiconductor, one of its predecessors, with the Dexerials Group’s technologies of controlling light and electricity to create unprecedented photonics solutions and to help resolve social issues. This will be the reason for its existence and it will tackle its work with a strong determination.
Dexerials and Kyoto Semiconductor will showcase their products and present the integrated company, DXPS, in their booth at the OFC 2024 exhibition that will start on March 26 in San Diego in the United States. We cordially invite visitors to the exhibition to drop by our booth. We look forward to seeing you at San Diego.
Change in sales structure after the launch of DXPS
Please see the diagram.
(Notes) |
* DXPC, Kyoto Semiconductor and DXPS are wholly owned subsidiaries of Dexerials Corporation. |
|
** After the launch of DXPS, OSDC will continue to manufacture microdevices under contract. |
|
*** Photonics products correspond to products that have been handled by DXPC and Kyoto Semiconductor. |
Participation in the OFC 2024 exhibition in San Diego, USA
OFC 2024 Exhibition
Date: Tuesday, March 26, 2024 to Thursday, March 28, 2024
Venue: San Diego Convention Center (San Diego, USA)
Stand number: 3814
Official website: https://www.ofcconference.org/en-us/home/
Products to be displayed
1. Optical semiconductor
2. Inorganic waveplate
3. Smart precision Adhesive
4. Anisotropic Conductive Film (ACF)
About Dexerials Corporation https://www.dexerials.jp/en/
Dexerials Corporation is a manufacturer providing functional materials for use in smartphones, automobiles and other domains in accordance with its corporate vision, Value Matters - Unprecedented innovation, unprecedented value. On a global scale, Dexerials Corporation manufactures and markets Anisotropic Conductive Film (ACF), optical elastic resin (SVR), anti-reflection film, surface mounted type fuses, industrial adhesives, double- and single-sided tapes and other electronic parts, junction materials, optical materials, and many other materials.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321222931/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom